Clinical trials: Depressed
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
The main objective is to evaluate the pharmacokinetics comparative studies in a single dose, multiple dose
- Trial name
- NCT02785614
- Testing
- trazodone hydrochloride prolonged-release tablet, trazodone hydrochloride tablet
- Where
- Hong Kong
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Major Depressive Disorder
Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
This study was a pharmacokinetic and safety evaluation of the S-adenosylmethionine formulation MSI-195, and a commercial comparator. The study was broken into two stages.
- Trial name
- NCT04623034
- Testing
- Ademetionine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- MSI Methylation Sciences, Inc.
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams [mg] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant…
- Trial name
- NCT07716098
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 348 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Depression Study In Elderly Patients
Major Depressive Disorder (MDD) Study in Elderly Outpatients
- Trial name
- NCT00067444
- Testing
- Paroxetine CR
- Where
- 46 sites in United States
- Volunteers
- 560 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Study of NSI-189 for Major Depressive Disorder
The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80…
- Trial name
- NCT02695472
- Testing
- 80 Milligrams NSI-189, 40 Milligrams NSI-189
- Where
- 13 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Insomnia, Depression
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
- Trial name
- NCT00232167
- Testing
- Indiplon, Sertraline
- Volunteers
- 380 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Safety Study of F2695 SR in Major Depressive Disorder
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
- Trial name
- LVM-MD-04 (NCT01034267)
- Testing
- F2695 SR
- Where
- 68 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social…
- Trial name
- NCT04524598
- Testing
- Limbix Spark, Psychoeducation
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Limbix Health, Inc.
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Lynparza Breast Cancer Clinical Experience Investigation
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Trial name
- NCT03590938
- Where
- 31 sites in Japan
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Stress Disorders, Post-Traumatic, Anxiety Disorders
Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics
This is an observational study to assess the change in several psychological screening tools before and after a series of six ketamine infusions in paramedics who suffer from post traumatic stress disorder as a result of working…
- Trial name
- NCT03947099
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Klarisana Physician Services PLLC
Breast Cancer
Online Stress Management and Coping Skills Training for Women With Breast Cancer
Stress Management interventions have been shown to decrease cancer-related distress, foster emotional growth and improve immune functioning during treatment for breast cancer.
- Trial name
- NCT01335152
- Testing
- Coping with Breast Cancer web-based workbook
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Talaria, Inc
Depression
Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
The primary purpose of this study is to determine if duloxetine plus non-drug intervention is more effective than duloxetine alone in patients with depression.
- Trial name
- NCT00494377
- Testing
- duloxetine
- Where
- Austria
- Volunteers
- 940 people
- Sponsor
- Eli Lilly and Company
Bipolar Depression, Suicidal Ideation
NRX101 Glx Biomarker Validation Study
Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD.
- Trial name
- NRX-GLX (NCT03402152)
- Testing
- NRX-101, Lurasidone HCl
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroRx, Inc.
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc